Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zinc, cancer study

This article was originally published in The Tan Sheet

Executive Summary

Stage III and IV head and neck cancer patients receiving zinc supplementation have a better three-year, local-free survival rate than matched control patients, according to researchers of the Chi-Mei Foundation Medical Center in Taiwan. In a double-blinded, randomized, placebo-controlled study beginning in 2003 and published in the International Journal of Radiation Oncology Biology Physics, 50 patients undergoing radiotherapy for two months took 75 mg per day of zinc supplement Pro-Z, a powder extracted from bovine prostate that is chelated to zinc. Patients in the experimental and control groups had similar results; patients with any of the four cancer stages had marginally better three-year LFS rates when supplemented with zinc, though insignificant. However, patients with stage III and IV cancer had notably better and significant LFS rates when taking Pro-Z and undergoing radiotherapy...

You may also be interested in...



Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.

Topics

UsernamePublicRestriction

Register

PS101167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel